These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 23890061)

  • 1. Turning tumors into vaccines: co-opting the innate immune system.
    van den Boorn JG; Hartmann G
    Immunity; 2013 Jul; 39(1):27-37. PubMed ID: 23890061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An overview of cancer immunotherapeutic strategies.
    Wahid B; Ali A; Rafique S; Waqar M; Wasim M; Wahid K; Idrees M
    Immunotherapy; 2018 Aug; 10(11):999-1010. PubMed ID: 30149763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harnessing the Microbiome to Enhance Cancer Immunotherapy.
    Nelson MH; Diven MA; Huff LW; Paulos CM
    J Immunol Res; 2015; 2015():368736. PubMed ID: 26101781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empowering dendritic cell cancer vaccination: the role of combinatorial strategies.
    Galati D; Zanotta S
    Cytotherapy; 2018 Nov; 20(11):1309-1323. PubMed ID: 30360963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.
    Monjazeb AM; Hsiao HH; Sckisel GD; Murphy WJ
    J Immunotoxicol; 2012; 9(3):248-58. PubMed ID: 22734880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coley's immunotherapy revived: Innate immunity as a link in priming cancer cells for an attack by adaptive immunity.
    Uher O; Caisova V; Hansen P; Kopecky J; Chmelar J; Zhuang Z; Zenka J; Pacak K
    Semin Oncol; 2019; 46(4-5):385-392. PubMed ID: 31739997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint modulation: rational design of combination strategies.
    Zamarin D; Postow MA
    Pharmacol Ther; 2015 Jun; 150():23-32. PubMed ID: 25583297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STING signaling: a key to therapeutic tumor immunity.
    Foote JB; Emens LA
    Immunotherapy; 2018 Jul; 10(9):729-731. PubMed ID: 30008260
    [No Abstract]   [Full Text] [Related]  

  • 9. Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies.
    Medina-Echeverz J; Hinterberger M; Testori M; Geiger M; Giessel R; Bathke B; Kassub R; Gräbnitz F; Fiore G; Wennier ST; Chaplin P; Suter M; Hochrein H; Lauterbach H
    Nat Commun; 2019 Nov; 10(1):5041. PubMed ID: 31695037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccines versus immunotherapy: overview of approaches in deciding between options.
    Dalgleish AG
    Hum Vaccin Immunother; 2014; 10(11):3369-74. PubMed ID: 25625932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines.
    Butt AQ; Mills KH
    Oncogene; 2014 Sep; 33(38):4623-31. PubMed ID: 24141774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral immunotherapy: using the tumor as the remedy.
    Marabelle A; Tselikas L; de Baere T; Houot R
    Ann Oncol; 2017 Dec; 28(suppl_12):xii33-xii43. PubMed ID: 29253115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunologic Targeting of Cancer Stem Cells.
    Zhang J; Li Q; Chang AE
    Surg Oncol Clin N Am; 2019 Jul; 28(3):431-445. PubMed ID: 31079798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Harnessing the power of the immune system to target cancer.
    Lizée G; Overwijk WW; Radvanyi L; Gao J; Sharma P; Hwu P
    Annu Rev Med; 2013; 64():71-90. PubMed ID: 23092383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fundamentals of Cancer Immunology and Their Application to Cancer Vaccines.
    Bullock TNJ
    Clin Transl Sci; 2021 Jan; 14(1):120-131. PubMed ID: 32770735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational design of vaccines: learning from immune evasion mechanisms of persistent viruses and tumors.
    Arens R
    Adv Immunol; 2012; 114():217-43. PubMed ID: 22449784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
    Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
    Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemical Strategies to Enhance the Therapeutic Efficacy of Toll-like Receptor Agonist Based Cancer Immunotherapy.
    Lee SN; Jin SM; Shin HS; Lim YT
    Acc Chem Res; 2020 Oct; 53(10):2081-2093. PubMed ID: 32966047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cells in tumor immunology and immunotherapy.
    Turtle CJ; Hart DN
    Curr Drug Targets; 2004 Jan; 5(1):17-39. PubMed ID: 14738216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trained immunity inducers in cancer immunotherapy.
    Sui Y; Berzofsky JA
    Front Immunol; 2024; 15():1427443. PubMed ID: 39081326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.